Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2017

Dec 19, 2017

32254_dirs_2017-12-19_36dc4a2a-b90b-482a-b961-8ef0b281f576.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2017-12-15

Reporting Person: Peterson Kristine (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-15 Employee Stock Option (right to buy) $1.77 A 40000 Acquired 2027-06-27 Common Stock (40000) Direct

Footnotes

F1: The option becomes exercisable in three equal annual installments beginning on June 27, 2018.